Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Corticosteroids in Acute GVHD
NCT02614612Phase 1Completed
- Sponsor
- Incyte
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Incyte. Primary endpoint: Safety and tolerability of study treatment. Started Dec 2015; status: completed.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02614612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614612.